Experimental ovarian cancer drug combo studied in early trial
NCT ID NCT05200364
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested a new drug called STRO-002 combined with Avastin (bevacizumab) in 58 people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The main goals were to check safety and find the right dose. The study was terminated early, so while it gathered some safety data, it does not yet show whether the combination works better than existing treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
STRO-002 (an antibody-drug conjugate) combined with bevacizumab (Avastin)
What this could lead to
If successful, this combination could offer a new treatment option for advanced ovarian cancer that has stopped responding to other therapies.
What could go wrong
This was a very early (Phase 1) trial focused on safety and dosing, not effectiveness. The study was terminated early, so results are limited and may not lead to a standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19017, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of South Florida,
Tampa, Florida, 33612, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States